Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Eur J Haematol
    April 2024
  1. RICHARDSON T, Scheid C, Herling M, Frenzel LP, et al
    Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trial.
    Eur J Haematol. 2024 Apr 14. doi: 10.1111/ejh.14210.
    >> Share

    March 2024
  2. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
    Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
    Eur J Haematol. 2024;112:371-378.
    >> Share

    February 2024
  3. HEGER JM, d'Hargues Y, Kleinert F, Mattlener J, et al
    Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
    Eur J Haematol. 2024 Feb 18. doi: 10.1111/ejh.14191.
    >> Share

  4. MASSOUD R, Naim H, Klyuchnikov E, Janson D, et al
    Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas.
    Eur J Haematol. 2024;112:276-285.
    >> Share

  5. HO M, Zanwar S, Paludo J
    Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Eur J Haematol. 2024;112:197-210.
    >> Share

    January 2024
  6. YAMAUCHI N, Maruyama D
    Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
    Eur J Haematol. 2024 Jan 3. doi: 10.1111/ejh.14166.
    >> Share

  7. ZEREMSKI V, Adolph L, Beer S, Berisha M, et al
    Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.
    Eur J Haematol. 2024 Jan 2. doi: 10.1111/ejh.14159.
    >> Share

  8. GUPTA S, Kohorst M, Alkhateeb HB
    Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2024;112:51-63.
    >> Share

    December 2023
  9. LOPEZ M, Kainthla R, Lazarte S, Chen W, et al
    Outcomes in Kaposi's sarcoma-associated herpesvirus -associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety-net hospital system.
    Eur J Haematol. 2023 Dec 28. doi: 10.1111/ejh.14163.
    >> Share

  10. RAMDANY H, Lofaro T, Deplano S
    The Haemato-Oncology Frailty (HOF) score to assess frailty in lymphoma.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14152.
    >> Share

  11. MORI T, Osumi T, Kada A, Ohki K, et al
    Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14148.
    >> Share

    October 2023
  12. BREINHOLT MF, Schejbel L, Gang AO, Nielsen TH, et al
    Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.
    Eur J Haematol. 2023;111:583-591.
    >> Share

    September 2023
  13. AGRAWAL V, Murphy L, Pourhassan H, Pullarkat V, et al
    Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 29. doi: 10.1111/ejh.14109.
    >> Share

  14. ZHU H, Zhuang Z, Wang W, Zhao D, et al
    Three cases of late-onset post CAR-T therapy isolated CNS relapse in R/R large B-cell lymphoma.
    Eur J Haematol. 2023 Sep 18. doi: 10.1111/ejh.14078.
    >> Share

  15. CHATTERJEE G, Dhende P, Raj S, Shetty V, et al
    15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14102.
    >> Share

  16. CAI F, Zhang J, Gao H, Shen H, et al
    Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14103.
    >> Share

    August 2023
  17. VAN HEEK L, Weindler J, Gorniak C, Kaul H, et al
    Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
    Eur J Haematol. 2023 Aug 29. doi: 10.1111/ejh.14093.
    >> Share

  18. KURTE MS, Siefen AC, Jakobs F, von Tresckow B, et al
    Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
    Eur J Haematol. 2023 Aug 29. doi: 10.1111/ejh.14095.
    >> Share

  19. AMITAI I, Roos K, Rashedi I, Jiang Y, et al
    PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.
    Eur J Haematol. 2023;111:191-200.
    >> Share

    July 2023
  20. MATTSSON A, Sylvan SE, Axelsson P, Ellin F, et al
    Idelalisib (PI3Kdelta inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
    Eur J Haematol. 2023 Jul 27. doi: 10.1111/ejh.14065.
    >> Share

    June 2023
  21. QIN Y, He X, Chen X, Xie Z, et al
    Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients.
    Eur J Haematol. 2023 Jun 9. doi: 10.1111/ejh.14013.
    >> Share

    May 2023
  22. CENCINI E, Rocco M, Ghio F, Simonetti F, et al
    Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone.
    Eur J Haematol. 2023 May 10. doi: 10.1111/ejh.13989.
    >> Share

    April 2023
  23. METZNER B, Muller TH, Casper J, Kimmich C, et al
    Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
    Eur J Haematol. 2023 Apr 24. doi: 10.1111/ejh.13985.
    >> Share

    March 2023
  24. ONG SY, Chen Y, Yun MTS, Ho Yew Leng A, et al
    Current perspectives on resistance to CAR T-cell therapy and strategies to improve efficacy in B-cell lymphoma.
    Eur J Haematol. 2023 Mar 29. doi: 10.1111/ejh.13964.
    >> Share

  25. BUEGE MJ, Drill E, Horwitz SM, LeVoir A, et al
    Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
    Eur J Haematol. 2023 Mar 27. doi: 10.1111/ejh.13971.
    >> Share

  26. KATZ OB, Perry C, Greenzaid SG, Ofir DY, et al
    Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study.
    Eur J Haematol. 2023 Mar 25. doi: 10.1111/ejh.13968.
    >> Share

  27. MITROVIC Z, Dujmovic D, Jaksic O, Kinda SB, et al
    Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: a real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
    Eur J Haematol. 2023 Mar 20. doi: 10.1111/ejh.13957.
    >> Share

  28. SHENG Z, Wang L
    Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: a network meta-analysis.
    Eur J Haematol. 2023 Mar 14. doi: 10.1111/ejh.13953.
    >> Share

    February 2023
  29. GAO H, Lin N, Gu Z, Zhao S, et al
    Up-front Autologous Hematopoietic Stem Cell Transplantation After First Complete Remission Improved Prognosis of Advanced Extra nodal NKT Cell Lymphoma: A Multicenter Real-World Study in China.
    Eur J Haematol. 2023 Feb 24. doi: 10.1111/ejh.13950.
    >> Share

  30. WANG Y, Li J, Xue TL, Tian S, et al
    Clinical, biological and outcome features of P2RY8-CRLF2 and CRLF2 over-expression in pediatric B-cell precursor acute lymphoblastic leukemia according to the CCLG-ALL 2008 and 2018 protocol.
    Eur J Haematol. 2023 Feb 22. doi: 10.1111/ejh.13948.
    >> Share

  31. YUE X, Hallett D, Liu Y, Basa E, et al
    Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic health record cohort study.
    Eur J Haematol. 2023;110:177-187.
    >> Share

  32. SHARGIAN L, Amit O, Bernstine H, Gurion R, et al
    The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter study.
    Eur J Haematol. 2023;110:149-156.
    >> Share

    January 2023
  33. TEY A, Schwarer J, Raffa R, Shi E, et al
    High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.
    Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13928.
    >> Share

  34. ELLIOTT EK, Hensen R, Haupt LM, Griffiths LR, et al
    Global reported impacts of COVID-19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic.
    Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13926.
    >> Share

    December 2022
  35. NGUYEN J, Wellard C, Chung E, Cheah CY, et al
    Clinical characteristics of Australian treatment-naive patients with classical Hodgkin Lymphoma from the Lymphoma and Related Diseases Registry.
    Eur J Haematol. 2022 Dec 20. doi: 10.1111/ejh.13915.
    >> Share

  36. PASQUI DM, Latorraca CDOC, Pacheco RL, Riera R, et al
    CAR-T cell therapy for patients with hematological malignancies. A systematic review.
    Eur J Haematol. 2022;109:601-618.
    >> Share

    November 2022
  37. JUUL SJ, Kicinski M, Schaapveld M, Rossetti S, et al
    Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials - a study based on the EORTC-Dutch late effects cohort linked data.
    Eur J Haematol. 2022 Nov 11. doi: 10.1111/ejh.13899.
    >> Share

  38. LIU X, Zhao X, Yang J, Wang H, et al
    High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma.
    Eur J Haematol. 2022 Nov 6. doi: 10.1111/ejh.13895.
    >> Share

    October 2022
  39. RIVA M, Tisi MC, Bertorelle R, Famengo B, et al
    IDH2(R172) mutation in angioimmunoblastic T-cell lymphoma: a retrospective multicenter case series.
    Eur J Haematol. 2022 Oct 20. doi: 10.1111/ejh.13885.
    >> Share

    September 2022
  40. DE FRANCESCO V, Manta R, Marmo R, Marmo C, et al
    Efficacy of H. pylori eradication in patients with diffuse large B-cell lymphoma of the stomach: a systematic review.
    Eur J Haematol. 2022 Sep 29. doi: 10.1111/ejh.13871.
    >> Share

  41. PAQUIN AR, Oyogoa E, McMurry HS, Kartika T, et al
    The Diagnosis and Management of Suspected Lymphoma in General Practice.
    Eur J Haematol. 2022 Sep 11. doi: 10.1111/ejh.13863.
    >> Share

  42. GILLESSEN S, Pluetschow A, Vucinic V, Ostermann H, et al
    JAK Inhibition with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: Final Results of A Phase II, Open Label, Multicenter Clinical Trial (JeRiCHO).
    Eur J Haematol. 2022 Sep 3. doi: 10.1111/ejh.13859.
    >> Share

  43. DANIEL A, Ghez D, Ravaiau C, Cavalieri D, et al
    Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.
    Eur J Haematol. 2022 Sep 1. doi: 10.1111/ejh.13858.
    >> Share

    July 2022
  44. QIU C, Du G
    Loss of LEF-1 expression as a diagnostic indicator for extranodal NK/T-cell lymphoma: An immunohistochemical study of 88 cases.
    Eur J Haematol. 2022 Jul 24. doi: 10.1111/ejh.13836.
    >> Share

  45. CENCINI E, Fabbri A
    Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma network)- authors' reply to Morris and colleagues.
    Eur J Haematol. 2022 Jul 18. doi: 10.1111/ejh.13831.
    >> Share

  46. MORRIS J, O'Reilly M, Sargent J, Murphy P, et al
    Pixantrone as a bridge to CAR-T treatment in high-grade transformation of follicular lymphoma.
    Eur J Haematol. 2022 Jul 18. doi: 10.1111/ejh.13829.
    >> Share

    June 2022
  47. ABBASOV E, Metzner B, Muller TH, Casper J, et al
    Herpes Zoster prophylaxis with low-dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation (ASCT).
    Eur J Haematol. 2022 Jun 10. doi: 10.1111/ejh.13810.
    >> Share

    May 2022
  48. VODICKA P, Benesova K, Janikova A, Prochazka V, et al
    Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Eur J Haematol. 2022 May 3. doi: 10.1111/ejh.13784.
    >> Share

    April 2022

  49. Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B-cell non-Hodgkin's lymphoma.
    Eur J Haematol. 2022 Apr 27. doi: 10.1111/ejh.13776.
    >> Share

    March 2022
  50. PENICHOUX J, Rio J, Kammoun L, Vermeulin T, et al
    Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first-line treatment for patients with diffuse large B-cell lymphoma.
    Eur J Haematol. 2022 Mar 13. doi: 10.1111/ejh.13767.
    >> Share

  51. EZE C, Friedrich I, Hadi I, Schmidt-Hegemann NS, et al
    Primary radiation therapy in stage I/II indolent orbital lymphoma - a comprehensive retrospective recurrence and toxicity analysis.
    Eur J Haematol. 2022 Mar 11. doi: 10.1111/ejh.13765.
    >> Share

    January 2022
  52. GRAEF CM, Godel P, Falderbaum P, Balke-Want H, et al
    Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt Lymphoma and High-Grade B-Cell Lymphoma.
    Eur J Haematol. 2022 Jan 28. doi: 10.1111/ejh.13747.
    >> Share

  53. CENCINI E, Mecacci B, Rocco M, Innocenti F, et al
    Pixantrone in patients with relapsed/refractory diffuse large b-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma Network).
    Eur J Haematol. 2022 Jan 20. doi: 10.1111/ejh.13745.
    >> Share

  54. FU H, Shen J, Zhou H, Zhang F, et al
    Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.
    Eur J Haematol. 2022 Jan 7. doi: 10.1111/ejh.13736.
    >> Share

  55. BEYAR-KATZ O, Kikozashvili N, Bar On Y, Amit O, et al
    Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells.
    Eur J Haematol. 2022;108:52-60.
    >> Share

    December 2021
  56. NOSAKA K, Crawford B, Yi J, Kuan W, et al
    A Systematic Review of Survival Outcomes for Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma.
    Eur J Haematol. 2021 Dec 4. doi: 10.1111/ejh.13728.
    >> Share

  57. WEISSINGER SE, Zahn M, Marienfeld R, Tessmer C, et al
    Combination of two monoclonal antibodies with SOCS1 N- and C-terminal binding sites to address SOCS1 status in B cells and B-cell lymphoma.
    Eur J Haematol. 2021 Dec 1. doi: 10.1111/ejh.13730.
    >> Share

    November 2021
  58. CUNNINGHAM I, Sosa SS, Hamele-Bena D
    A single organ microenvironment and the common features of tumors of leukemia, lymphoma, and myeloma cells growing there. A literature review.
    Eur J Haematol. 2021 Nov 15. doi: 10.1111/ejh.13727.
    >> Share

  59. SMITH T, Cunningham-Rundles C
    Lymphoid malignancy in common variable immunodeficiency in a single-center cohort.
    Eur J Haematol. 2021;107:503-516.
    >> Share

    October 2021
  60. FREITAS AC, Carvalho IP, Esteves S, Salgado L, et al
    End of treatment FDG-PET in primary mediastinal B-cell lymphoma treated with R-chemotherapy: Prognostic indicator and implications for consolidation radiotherapy.
    Eur J Haematol. 2021 Oct 2. doi: 10.1111/ejh.13715.
    >> Share

  61. LACOMBE V, Nunes Gomes C, Robin JB, Thepot S, et al
    Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations.
    Eur J Haematol. 2021;107:489-496.
    >> Share

    September 2021
  62. BRIAND M, Gerard S, Gauthier M, Garric M, et al
    Impact of therapeutic management and geriatric evaluation on patient of 80 years and older with diffuse large B-cell lymphoma on survival: a systematic review.
    Eur J Haematol. 2021 Sep 8. doi: 10.1111/ejh.13704.
    >> Share

  63. KUIJVENHOVEN MA, Wilhelm AJ, Meijer E, Janssen JJWM, et al
    TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study).
    Eur J Haematol. 2021;107:364-369.
    >> Share

  64. VERLINDEN A, Schroyens WA, Gadisseur AP
    Clinical and microbiological impact of long-term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia.
    Eur J Haematol. 2021;107:377-379.
    >> Share

  65. ATTMAN E, Syrjanen J, Lyytikainen O, Ollgren J, et al
    Healthcare-associated blood stream infections in hematological patients in Finland during the years 2006-2016.
    Eur J Haematol. 2021;107:311-317.
    >> Share

    July 2021
  66. METZNER B, Pott C, Muller TH, Casper J, et al
    Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
    Eur J Haematol. 2021 Jul 20. doi: 10.1111/ejh.13691.
    >> Share

  67. WIGHT J, Wai SH, Shen E, Lee ST, et al
    Predicting primary treatment failure using interim FDG-PET scanning in Diffuse large B-cell lymphoma.
    Eur J Haematol. 2021 Jul 8. doi: 10.1111/ejh.13684.
    >> Share

  68. WU X, Nowakowski KE, Abeykoon JP, Manske M, et al
    MCIR1: A Patient-Derived Mantle Cell Lymphoma Line for Discovering New Treatments for Ibrutinib Resistance.
    Eur J Haematol. 2021 Jul 2. doi: 10.1111/ejh.13682.
    >> Share

  69. MORTENSEN JB, Monrad I, Enemark MB, Ludvigsen M, et al
    Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Eur J Haematol. 2021;107:81-91.
    >> Share

  70. WEISSINGER SE, Zahn M, Marienfeld R, Tessmer C, et al
    A new reliable and highly specific monoclonal antibody to detect the C-terminal region of silencer of cytokine signaling 1.
    Eur J Haematol. 2021;107:74-80.
    >> Share

    May 2021
  71. RENAUD L, Bossard JB, Carpentier B, Terriou L, et al
    Treatment with temozolomide and ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL).
    Eur J Haematol. 2021 May 21. doi: 10.1111/ejh.13667.
    >> Share

  72. SHANMUGASUNDARAM K, Goyal S, Switchenko J, Calzada O, et al
    Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival.
    Eur J Haematol. 2021 May 11. doi: 10.1111/ejh.13649.
    >> Share

  73. SIEG N, Naendrup JH, Godel P, Balke-Want H, et al
    Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma - feasibility of MTX-based regimens in clinical routine.
    Eur J Haematol. 2021 May 7. doi: 10.1111/ejh.13639.
    >> Share

  74. HANSEN S, Alduaij W, Biggs CM, Belga S, et al
    Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Eur J Haematol. 2021;106:654-661.
    >> Share

    April 2021
  75. YUDA S, Maeshima AM, Taniguchi H, Ito Y, et al
    Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.
    Eur J Haematol. 2021 Apr 27. doi: 10.1111/ejh.13637.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016